Marc Rubin's most recent trade in Curis Inc was a trade of 14,400 Non Qualified Stock Option done . Disclosure was reported to the exchange on May 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 14,400 | 14,400 | - | - | Non Qualified Stock Option | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 1,600 | 1,600 | - | - | Non Qualified Stock Option | |
| Galectin Therapeutics Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 4,250 | 4,250 | - | - | Non Qualified Stock Option | |
| Galectin Therapeutics Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2023 | 85,000 | 85,000 | - | - | Non Qualified Stock Option | |
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 85,000 | 85,000 | - | - | Non Qualified Stock Option | |
| Galectin Therapeutics Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Titan Pharmaceuticals, Inc... | Marc Rubin | Director, Executive Chairman | 05 Jan 2022 | 65,000 | 65,000 | - | - | Option to Purchase Common Stock | ||
| Galectin Therapeutics Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Titan Pharmaceuticals, Inc... | Marc Rubin | Director, Executive Chairman | 10 Feb 2021 | 150,000 | 150,000 | - | - | Option to Purchase Common Stock | ||
| Curis Inc | Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 33,000 | 33,000 | - | - | Non Qualified Stock Option |